

NUCLEOPHILIC SUBSTITUTION REACTIONS OF 4,5-DICHLORO-2-METHYL-6-NITRO-2*H*-PYRIDAZIN-3-ONE

Kyu-Tae Chang,^c Jeum-Jong Kim,^b Young-Kook Kim,^d Ho-Yong park,^c
Byung-Hwa Hyun,^c Motoo Shiro,[†] Yong-Jin Yoon,^{b*} and Woo Song Lee^{a*}


^aBK 21-School of Molecular Science & Department of Chemistry, Korea Advanced Institute of Science and Technology, Taejon 305-701, Korea

^bDepartment of Chemistry & Research Institute of Natural Sciences, Gyeongsang National University, Chinju 660-701, Korea

^cGenetic Resources Center and ^dLaboratory of Cardiovascular, Korea Research Institute of Bioscience and Biotechnology, Taejon 305-333, Korea

Abstract-4,5-Dichloro-2-methyl-6-nitro-2*H*-pyridazin-3-one (**1**) reacts with various substituted phenols and 2-mercaptopyrimidine in the presence of NaH or K₂CO₃ to give 3(2*H*)-pyridazinones (**4**, **5a-9a**, **5b-9b**, and **7c**) in high yields. The regiochemistry was confirmed by X-Ray analysis and nOe experiments.

Since the discovery that pyrrolo[2,3-*d*]pyrimidine or pyrrolo[2,3-*c*]pyridazine exhibited antiproliferative activity and/or antiviral activity, much attention has been paid to the development of convenient and efficient routes for synthesis of heterocyclic bases.¹ As a modification of heterocyclic base, we reported recently the results for the synthesis of new *N*-acyclonucleosides containing pyrrolo[2,3-*c*]pyridazine skeleton utilizing 4,5-dichloro-2-methyl-6-nitro-2*H*-pyridazin-3-one (**1**).² Then, the nitro group at 6-position of compound (**1**) is essential for the synthesis of fused-heterocycles containing pyridazinone and various trisubstituted pyridazin-3-ones. In connection with nucleophilic substitution reaction of halogens using various trisubstituted pyridazin-3-ones,³ we reported that the methoxylation of compound (**1**) under the K₂CO₃/MeOH system gave 4-methoxylated pyridazinone (**2**) as a major product and 5-methoxylated pyridazinone (**3**) as a minor product in 62 and 28% yields, respectively (Scheme 1).⁴ In order to examine the substitution reaction toward nucleophiles and further synthetic application, we investigated in detail the substitution reaction of 4,5-dichloro-2-methyl-6-nitro-2*H*-pyridazin-3-one (**1**) with various substituted phenols and mercaptopyrimidine in the presence of NaH or K₂CO₃.



Scheme 1

The requisite compound (**1**) was prepared by Yoon's method,² namely, nitration of 4,5-dichloro-2-methyl-2*H*-pyridazin-3-one with potassium nitrate and concentrated sulfuric acid gave 4,5-dichloro-2-methyl-6-nitro-2*H*-pyridazin-3-one (**1**) in 82% yield. Subsequently, we investigated nucleophilic substitution of halogen of compound (**1**) utilizing phenoxide or mercaptopyrimidine sulfone anion which was prepared by treatment of various substituted phenols or mercaptopyrimidine with a base NaH or K₂CO₃. The results are summarized in Table 1. Interestingly, compound (**1**) regioselectively reacted with *p*-methoxyphenol in the presence of NaH at 0 °C to give the 5-chloro-4-(4-methoxyphenoxy)-2-methyl-6-nitro-2*H*-pyridazin-3-one (**4**) as the sole product in a good yield (Run 1). Compound (**1**) was treated with phenol (or *p*-chlorophenol) and NaH in THF to produce the corresponding compounds (**5a**) (56%), (**5b**) (16%), (**6a**) (74%), and (**6b**) (15%), respectively (Runs 4 and 6). Similar treatment of **1** with *p*-cyanophenol and NaH gave compounds (**7a**) (48%), (**7b**) (24%), and 4,5-bis(4-cyanophenoxy)-2-methyl-6-nitro-2*H*-pyridazin-3-one (**7c**) (8%) (Run 8). The reaction of **1** with *p*-nitrophenol proceeded under the mild conditions to furnish the corresponding **8a** (55%) and **8b** (17%) (Run 10). Tentatively, compound (**1**) was treated with mercaptopyrimidine to afford the corresponding **9a** (60%) and **9b** (29%) (Run 12) (*Method A*).

On the other hand, we attempted the nucleophilic substitution of compound (**1**) under the refluxing condition using K₂CO₃. The results are summarized in Table 1. Namely, compound (**1**) reacted with *p*-methoxyphenol to give only 5-chloro-4-(4-methoxyphenoxy)-2-methyl-6-nitro-2*H*-pyridazin-3-one (**4**) in 97% yield (Run 2) (*Method B*), whereas this reaction did not proceed when used AgNO₃ (Run 3). According to *Method B*, compound (**1**) was subjected to various nucleophilic substitutions to give the corresponding **5a-9a**, **5b-9b**, and **7c** in high yields, respectively (Runs 5, 7, 9, 11, and 13). Although the regioselectivity in these reactions employing K₂CO₃ is not variable, the yield was much higher than that using NaH. In general, nucleophilic substitution of halogens of the heterocycles using potassium alkoxide anion has been proven to be a conventional method for the chemical manipulation of heterocycles.³ More recently, Lemièrè group⁵ reported that palladium-catalyzed amination on 4-chloro-3(2*H*)-pyridazinones, while using an excess of K₂CO₃ as a base, could be a general and efficient approach to different aryl- and

heteroarylaminopyridazinones. However, it is of some limited use for the multihalogens-substituted pyridazinones because it seems to be difficult to obtain the product selectively.






Table 1. Nucleophilic substitution using 4,5-dichloro-2-methyl-6-nitropyridazin-3-one

Run	Nucleophile	Base ^a	Temp	Time	Yield (%) of 4,5a-9a ^b	Yield (%) of 5b-9b ^b	Yield (%) of 7c ^b
1	<i>p</i> -MeOC ₆ H ₄ OH	N	0 °C	25 min	4 (70)	none	
2	"	K	reflux	6 h	4 (97)	"	
3	"	A	"	7 h	none	"	
4	PhOH	N	0 °C	20 min	5a (56)	5b (16)	
5	"	K	reflux	24 h	5a (80)	5b (19)	
6	<i>p</i> -ClC ₆ H ₄ OH	N	0 °C	20 min	6a (74)	6b (15)	
7	"	K	reflux	8 h	6a (72)	6b (20)	
8	<i>p</i> -CNC ₆ H ₄ OH	N	rt	2 h	7a (48)	7b (24)	7c (8)
9	"	K	reflux	16 h	7a (60)	7b (22)	7c (14)
10	<i>p</i> -NO ₂ C ₆ H ₄ OH	N	rt	3 h	8a (55)	8b (17)	
11	"	K	"	4 h	8a (60)	8b (33)	
12		N	0 °C	1 h	9a (60)	9b (29)	
13	"	K	rt	3 h	9a (67)	9b (25)	

a) Base: N = NaH, K = K₂CO₃, A = AgNO₃. b) Isolated yields.



Scheme 2

In order to determine the position of *p*-methoxyphenoxy group on **4**, reduction of compound (**4**) with iron/ammonium chloride/chloroform/water system⁶ afforded the corresponding 6-amino-5-chloro-4-(4-

methoxyphenoxy)-2-methyl-2*H*-pyridazin-3-one (**10**). Compound (**10**) was dehalogenated with Pd/C under hydrogen atmosphere to give 6-amino-4-(4-methoxyphenoxy)-2-methyl-2*H*-pyridazin-3-one (**11**) in 80% yield. Then, the position of the *p*-methoxyphenoxy group for **4** was established by the nOe [between C5-H proton and C6-NH₂ protons (or phenyl protons)] experiments (Scheme 2). The structures of 2*H*-pyridazin-3-ones (**4**, **5a-9a**, **5b-9b**, and **7c**) were confirmed on the basis of their characteristic spectroscopic data. Also, the substituted position of the *p*-chlorophenol group on **6a** and **6b** was easily established by X-Ray crystallographic analysis (Figure 1).⁷




Figure 1 X-Ray crystal structures of **6a** and **6b**.

On the basis of the X-Ray representation or ortep drawing of **6a** and **6b**, the ¹H-NMR spectra of all products showed that the chemical shift values of 2-CH₃ group [each singlet for (δ 3.69-3.83 ppm) **4**, **5a-9a**] are lower than those of 2-CH₃ group [each singlet for (δ 3.80-3.98 ppm) **5b-9b**]. The ¹³C-NMR spectra also show carbon signals of 2-CH₃ group in a range of δ 40.2-41.2 ppm for **4**, **5a-9a**, whereas δ 41.2-44.2 ppm for **5b-9b**. The chemical behavior of these compounds is also agreement with the assigned structure; namely, 4-substituted 2*H*-pyridazin-3-ones (**4**, **5a-9a**) show a strong band in a range of 1665-1685 cm⁻¹ due to attributed to the amide group, whereas 1669-1688 cm⁻¹ for compounds (**5b-9b**).

In conclusion, the nucleophilic substitution of halogens of **1** with various substituted phenols or 2-mercaptopyrimidine has been achieved. All compounds obtained should be useful for synthesis of heterocyclic bases in the nucleoside or acyclonucleoside chemistry.

EXPERIMENTAL

Melting points were determined with a Thomas-Hoover capillary apparatus and are uncorrected. NMR spectra were obtained on a Bruker FTNMR-DRX 500 spectrometer with chemical shift values reported in units (part per million) relative to an internal standard (tetramethylsilane). IR spectral data were obtained on a Hitachi 270-50 spectrophotometer. Elemental analyses were performed with Perkin Elmer 240C. X-Ray diffraction data were obtained with a Rigaku AFC7R diffractometer with filtered Cu-K α radiation and a rotating anode generator. Open chromatography was carried out with silica gel 60 (70-230 mesh, Merck). The column was packed as slurries with the elution solvent.

Reaction of 1 with methoxyphenol

General procedures

The reaction was carried out in two different experimental conditions.

5-Chloro-4-(4-methoxyphenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (4)

Method A: To a suspension solution of NaH (60% in mineral oil, 71.6 mg, 1.79 mmol) in THF (10 mL) was added a solution of *p*-methoxyphenol (222.2 mg, 1.79 mmol) in 5 mL of THF at 0 °C. After being stirred for 25 min, the solution of **1** (400 mg, 1.79 mmol) in THF (10 mL) was added slowly. After 25 min, the reaction mixture was quenched by addition of 5% HCl and then extracted with CH₂Cl₂. The combined organic layer was washed with a saturated aqueous NaHCO₃ solution, brine, and dried over anhydrous MgSO₄. Filtration and evaporation gave a residue, which was purified by column chromatography on silica gel (EtOAc : hexane = 1 : 2) to give 5-chloro-4-(4-methoxyphenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (**4**) (557.9 mg, 70%) as pale yellow prisms, mp 86-88 °C (CH₂Cl₂/hexane); IR (KBr) 3019, 2970, 1681, 1579, 1499 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.69 (s, 3H), 3.71 (s, 3H), 6.86 (d, *J* = 7.0 Hz, 2H), 6.95 (d, *J* = 7.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 40.9, 56.1, 115.1, 115.4, 118.6, 120.2, 149.3, 150.6, 155.6, 157.1. Anal. Calcd for C₁₂H₁₀N₃O₅Cl: C, 46.24; H, 3.23; N, 13.48. Found: C, 46.39; H, 3.02; N, 13.25.

Method B: A mixture of **1** (400 mg, 1.79 mmol), K₂CO₃ (62.2 mg, 1.79 mmol) and *p*-methoxyphenol (222.2 mg, 1.79 mmol) in 10 mL of THF was refluxed for 6 h. After cooling to rt, the reaction mixture was quenched by addition of 5% HCl and then extracted with CH₂Cl₂. The combined organic layer was washed with a saturated aqueous NaHCO₃ solution, brine, and dried over anhydrous MgSO₄. Filtration and evaporation gave a residue, which was purified by column chromatography on silica gel (EtOAc : hexane = 1 : 2) to give 5-chloro-4-(4-methoxyphenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (**4**) (543.4 mg, 97%).

Reaction of 1 with phenol

Following the *method A*, **5a** and **5b** were obtained in 56 and 16% yields, respectively (purified by column chromatography, with EtOAc : hexane = 1 : 6).

5-Chloro-2-methyl-6-nitro-4-phenoxy-2H-pyridazin-3-one (5a)

Pale yellow prisms; mp 105-106 °C (CH₂Cl₂/hexane); IR (KBr) 3048, 2949, 1685, 1582, 1272 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.83 (s, 3H), 7.02 (m, 2H), 7.22 (m, 1H), 7.39 (m, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 40.6, 116.9, 120.7, 124.9, 129.8, 146.2, 149.8, 155.1, 155.2. Anal. Calcd for C₁₁H₈N₃O₄Cl: C, 46.91; H, 2.86; N, 14.92. Found: C, 46.83; H, 2.62; N, 15.12.

4-Chloro-2-methyl-6-nitro 5-phenoxy-2H-pyridazin-3-one (5b)

Pale yellow prisms; mp 145-147 °C (CH₂Cl₂/hexane); IR (KBr): 3057, 2949, 1686, 1582, 1272 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.92 (s, 3H), 6.94 (m, 2H), 7.18 (m, 1H), 7.36 (m, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 41.5, 116.2, 124.9, 128.6, 130.1, 146.0, 151.2, 154.9, 158.3. Anal. Calcd for C₁₁H₈N₃O₄Cl: C, 46.91; H, 2.86; N, 14.92. Found: C, 47.15; H, 2.58; N, 14.70.

Following the *method B*, compounds (**5a**) and (**5b**) were obtained in 80 and 19% yields, respectively.

Reaction of 1 with p-chlorophenol

Following the *method A*, **6a** and **6b** were obtained in 74 and 15% yields, respectively (purified by column chromatography, with EtOAc : hexane = 1 : 2).

5-Chloro-4-(4-chlorophenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (6a)

Pale yellow prisms; mp 90-91 °C (CH₂Cl₂/hexane); IR (KBr): 3088, 1667, 1582, 1484, 1359, 1203 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.72 (s, 3H), 6.87 (d, *J* = 9.0 Hz, 2H), 7.24 (d, *J* = 9.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 41.2, 118.8, 121.5, 130.4, 130.8, 146.5, 150.0, 154.1, 155.5. Anal. Calcd for C₁₁H₇N₃O₄Cl₂: C, 41.80; H, 2.23; N, 13.29. Found: C, 41.50; H, 2.02; N, 13.48.

4-Chloro-5-(4-chlorophenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (6b)

Pale yellow prisms; mp 152 °C (CH₂Cl₂/hexane); IR (KBr) 2968, 1677, 1590, 1486, 1377 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.85 (s, 3H), 6.82 (d, *J* = 9.0 Hz, 2H), 7.25 (d, *J* = 9.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 44.2, 120.2, 120.5, 131.5, 132.9, 148.4, 156.0, 156.1, 160.8. Anal. Calcd for C₁₁H₇N₃O₄Cl₂: C, 41.80; H, 2.23; N, 13.29. Found: C, 41.63; H, 2.32; N, 13.41.

Following the *method B*, compounds (**6a**) and (**6b**) were obtained in 72 and 20% yields, respectively.

Reaction of 1 with p-cyanophenol

Following the *method A*, **7a**, **7b**, and **7c** were obtained in 48, 24, and 8% yields, respectively (purified by column chromatography, with EtOAc : hexane = 1 : 2).

5-Chloro-4-(4-cyanophenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (7a)

Colorless prisms; mp 130-131 °C (CH₂Cl₂/hexane); IR (KBr) 3099, 2999, 2230, 1684, 1497, 1206 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.82 (s, 3H), 7.08 (d, *J* = 6.8 Hz, 2H), 7.68 (d, *J* = 6.8 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 40.8, 108.8, 117.6, 118.0, 122.0, 134.2, 132.5, 148.6, 154.7, 157.8. Anal. Calcd for C₁₂H₇N₄O₄Cl: C, 47.00; H, 2.30; N, 18.27. Found: C, 47.23; H, 2.42; N, 18.51.

4-Chloro-5-(4-cyanophenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (7b)

Colorless prisms; mp 189-190 °C (CH₂Cl₂/hexane); IR (KBr) 3061, 2230, 1676, 1591, 1499, 1286 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.95 (s, 3H), 7.05 (d, *J* = 9.0 Hz, 2H), 7.69 (d, *J* = 9.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 42.1, 109.2, 117.1, 118.2, 130.1, 134.9, 143.5, 145.2, 157.9, 158.2. Anal. Calcd for C₁₂H₇N₄O₄Cl: C, 47.00; H, 2.30; N, 18.27. Found: C, 47.33; H, 2.12; N, 18.01.

4,5-Bis-(4-cyanophenoxy)-2-methyl-6-nitro-2H-pyridazin-3-one (7c)

Colorless prisms; mp 159-160 °C (CH₂Cl₂/*n*-hexane); IR (KBr) 3098, 2993, 2227, 1677, 1596, 1497, 1214 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.89 (s, 3H), 6.86 (d, *J* = 9.0 Hz, 2H), 7.03 (d, *J* = 9.0 Hz, 2H), 7.58 (d, *J* = 9.0 Hz, 2H), 7.62 (d, *J* = 9.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 41.4, 109.1, 109.3, 117.5, 117.7, 118.1, 118.3, 134.5, 134.7, 139.4, 142.0, 144.3, 157.4, 157.7, 158.5. Anal. Calcd for C₁₉H₁₁N₅O₅: C, 58.62; H, 2.85; N, 17.99. Found: C, 58.80; H, 3.01; N, 17.72.

Following the *method B*, compounds (**7a**, **7b**, and **7c**) were obtained in 60, 22, and 14% yields, respectively.

Reaction of 1 with *p*-nitrophenol

Following the *method A*, **8a** and **8b** were obtained in 55 and 17% yields, respectively (purified by column chromatography, with EtOAc : hexane = 1 : 3).

5-Chloro-2-methyl-4-(4-nitrophenoxy)-6-nitro-2H-pyridazin-3-one (8a)

Yellow needles; mp 88-89 °C (CH₂Cl₂/hexane); IR (KBr) 3075, 1674, 1584, 1520, 1347, 1207 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.76 (s, 3H), 7.03 (d, *J* = 9.1 Hz, 2H), 8.19 (d, *J* = 9.1 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 41.2, 117.5, 122.5, 126.3, 126.6, 144.9, 148.9, 155.1, 159.5. Anal. Calcd for C₁₁H₇N₄O₆Cl: C, 40.45; H, 2.16; N, 17.15. Found: C, 40.23; H, 2.32; N, 17.34.

4-Chloro-2-methyl-5-(4-nitrophenoxy)-6-nitro-2H-pyridazin-3-one (8b)

Yellow needles; mp 136-137 °C (CH₂Cl₂/hexane); IR (KBr) 3072, 1688, 1582, 1517, 1345, 1225 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.98 (s, 3H), 7.10 (d, *J* = 7.1 Hz, 2H), 8.30 (d, *J* = 7.1 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 42.1, 116.6, 126.3, 126.6, 130.2, 144.8, 145.2, 158.2, 159.3. Anal. Calcd for C₁₁H₇N₄O₆Cl: C, 40.45; H, 2.16; N, 17.15. Found: C, 40.68; H, 2.22; N, 16.98.

Following the *method B*, compounds (**8a**) and (**8b**) were obtained in 60 and 33% yields, respectively.

Reaction of 1 with 2-mercaptopyrimidine

Following the *method A*, **9a** and **9b** were obtained in 60 and 29% yields, respectively (purified by column chromatography, with EtOAc).

5-Chloro-4-(2-mercaptopyrimidyl)-2-methyl-6-nitro-2H-pyridazin-3-one (9a)

Yellow prisms; mp 118-119 °C (CH₂Cl₂/hexane); IR (KBr) 3034, 2997, 1665, 1556, 1374 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.76 (s, 3H), 7.05 (t like, *J* = 4.8 Hz, 1H), 8.45 (d, *J* = 4.6 Hz, 2H); ¹³C-NMR (125

MHz, CDCl₃) δ 40.2, 117.4, 133.1, 135.8, 144.3, 155.9, 156.8, 166.6. Anal. Calcd for C₉H₆N₅O₃SCl: C, 36.07; H, 2.02; N, 23.37; S, 10.70. Found: C, 36.38; H, 2.32; N, 23.59; S, 10.92.

4-Chloro-5-(2-mercaptopyrimidyl)-2-methyl-6-nitro-2H-pyridazin-3-one (9b)

Yellow prisms; mp 151-153 °C (CH₂Cl₂/hexane); IR (KBr) 3040, 1669, 1553, 1378, 1167 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.80 (s, 3H), 7.02 (t like, *J* = 4.8 Hz, 1H), 8.43 (d, *J* = 4.9 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 41.2, 118.2, 133.7, 143.7, 148.0, 157.1, 157.6, 168.0. Anal. Calcd for C₉H₆N₅O₃SCl: C, 36.07; H, 2.02; N, 23.37; S, 10.70. Found: C, 36.29; H, 1.98; N, 23.03; S, 10.98.

Following the *method B*, compounds (**9a**) and (**9b**) were obtained in 67 and 25% yields, respectively.

6-Amino-5-chloro-4-(4-methoxyphenoxy)-2-methyl-2H-pyridazin-3-one (10)

A mixture of **4** (1.2 g, 3.86 mmol), NH₄Cl (1.2 g, 0.02 mol), Fe (1.0 g, 0.018 mol), CHCl₃ (20 mL), and H₂O (20 mL) was refluxed for 2 h. The mixture was cooled to rt, filtered using Celite 545 resin, and washed with CHCl₃ (100 mL). The combined filtrate was evaporated under reduced pressure to give a residue, which was purified by column chromatography on silica gel (CHCl₃ : MeOH = 10 : 1) to give **10** (1.03 g, 95%) as colorless prisms, mp 178-179 °C (CH₂Cl₂/hexane); IR (KBr) 3350, 3280, 2950, 1630, 1590 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.60 (s, 3H), 3.77 (s, 3H), 4.45 (s, 2H), 6.83 (d, *J* = 10.5 Hz, 2H), 6.92 (d, *J* = 10.5 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 39.14, 55.65, 114.62, 117.67, 119.80, 144.67, 148.92, 149.78, 154.54, 156.02. Anal. Calcd for C₁₂H₁₂N₃O₃Cl: C, 51.16; H, 4.29; N, 14.92. Found: C, 51.38; H, 4.40; N, 14.78.

6-Amino-4-(4-methoxyphenoxy)-2-methyl-2H-pyridazin-3-one (11)

A mixture of **10** (500 mg, 1.77 mmol), Pd/C (250 mg), and MeOH (30 mL) was stirred for 5 h under hydrogen atmosphere at rt. The mixture was filtered using Celite 545 resin and washed with CHCl₃ (50 mL). The combined filtrate was evaporated under reduced pressure to give a residue, which was purified by column chromatography on silica gel (EtOAc : hexane = 1 : 1) to give **11** (350 mg, 80%) as yellow prisms, mp 200-202 °C (CH₂Cl₂/hexane); IR (KBr) 3480, 3080, 2950, 1740, 1680, 1590 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.64 (s, 3H), 3.82 (s, 3H), 3.97 (s, 2H), 5.83 (s, 1H), 6.92 (d, *J* = 9.0 Hz, 2H), 7.02 (d, *J* = 9.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 39.29, 55.65, 102.01, 122.05, 146.68, 147.24, 154.81, 156.78, 157.55. Anal. Calcd for C₁₂H₁₃N₃O₃: C, 58.29; H, 5.30; N, 17.00. Found: C, 58.40; H, 5.40; N, 17.22.

ACKNOWLEDGEMENTS

This work was supported by Korea Research Foundation Grant (KRF-2000-015-DP0281), in part the Research Grant HSS0360033 Ministry of Scientific & Technology, Korea, and the Brain Korea 21 Project.

REFERENCES AND NOTES

- † Present address: Rigaku Corporation, 3-9-2 Matsubara-cho, Akishima-shi, Tokyo 196-8666, Japan.
1. T. E. Renau, L. L. Wotring, J. C. Drach, and L. B. Townsend, *J. Med. Chem.*, 1996, **39**, 873; T. E. Renau, C. Kennedy, R. G. Ptak, J. M. Breitenbach, J. C. Drach, and L. B. Townsend, *ibid.*, 1996, **39**, 3470.
 2. J.-W. Park, D.-H. Kweon, Y.-J. Kang, W. S. Lee, S.-D. Cho, and Y.-J. Yoon, *J. Heterocycl. Chem.*, 2000, **37**, 5.
 3. S.-Y. Choi, S. C. Shin, and Y.-J. Yoon, *J. Heterocycl. Chem.*, 1991, **28**, 385; S.-Y. Choi, S.-G. Lee, and Y.-J. Yoon, *ibid.*, 1991, **28**, 1235; D.-H. Kweon, S.-D. Cho, S.-K. Kim, J.-W. Chung, and Y.-J. Yoon, *ibid.*, 1996, **33**, 1915; W.-Y. Choi, S.-D. Cho, S.-K. Kim, and Y.-J. Yoon, *ibid.*, 1997, **34**, 1307.
 4. S.-G. Lee, S.-Y. Choi, and Y.-J. Yoon, *J. Heterocycl. Chem.*, 1992, **29**, 1409; J.-W. Park, J.-J. Kim, H.-K. Kim, Y.-J. Kang, W. S. Lee, and Y.-J. Yoon, *ibid.*, 2000, **37**, 1603.
 5. J. Kosmrlj, B. U. W. Maes, G. L. F. Lemièrre, and A. Haemers, *Synlett*, 2000, 1581.
 6. S.-D. Cho, W.-Y. Choi, S.-G. Lee, Y.-J. Yoon, and S. C. Shin, *Tetrahedron Lett.*, 1996, **37**, 7059.
 7. The crystallographic data of **6a** and **6b**. **6a** : C₁₁H₇N₃O₄Cl₂, F.W. = 316.10, orthorhombic, a = 13.198(2) Å, b = 11.524(2) Å, c = 8.377(1) Å, V = 1274.1(6) Å³, space group Pna2₁ (#33), Z = 4, D_{calc} = 1.648 g/cm³, F₀₀₀ = 640.00, μ(MoKα) = 5.25 cm⁻¹; **6b** : C₁₁H₇N₃O₄Cl₂, F.W. = 316.10, monoclinic, a = 13.960(5) Å, b = 5.602(1) Å, c = 17.422(8) Å, β = 107.03 (1)°, V = 1302.8(8) Å³, space group P2₁/c(#14), Z = 4, D_{calc} = 1.611 g/cm³, F₀₀₀ = 640.00, μ(MoKα) = 5.14 cm⁻¹.